Posted on

On 11 August 2025, the Secretary of Health (SOH) approved the inclusion of the following health technologies (HTs) in the Philippine National Formulary through the Department of Health (DOH) Department Circular 2025-0341. This approval follows the recommendations previously submitted by the HTA Council:

  1. Pancreatin [150 mg capsule] for Pancreatic Exocrine Insufficiency (PEI) in adults with pancreatic cancer
  2. Pretomanid [200mg tablet] for the treatment of drug-resistant tuberculosis
  3. Pyronaridine tetraphosphate + Artesunate [180 mg/ 60 mg film-coated tablet] for second-line treatment of uncomplicated malaria infection caused by Plasmodium falciparum or Plasmodium vivax among adults and children weighing 20 kg or more
  4. Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccine as an active booster immunization against tetanus, diphtheria and pertussis
  5. Plasma-derived Coagulation Factor VIII [250 IU/10 mL (25 IU/mL); 250 IU/5mL (50 IU/mL); 500 IU/10mL (50 IU/mL); 500 IU/5ml (100 IU/mL); 1000 IU/10mL (100IU/mL) powder solution for IV]
  6. Factor VIII Inhibitor Bypassing Activity [500U/10mL; 1000U/20mL; 2500U/50mL powder solution for infusion (IV)]
  7. Japanese Encephalitis Vaccine [(1) Live, Attenuated; (2) Inactivated, absorbed] for the prevention of japanese encephalitis among children 9 to 59 months old in high-risk areas
  8. Silver Diamine Fluoride 38% Clear Topical Solution for prevention and arrest of dentine caries in primary and permanent teeth among children 12 months to 10 years old
  9. Pneumococcal Conjugate Vaccine (PCV) for Infants less than 1 year old and children aged 13 to 23 months for catch-up immunization:
    • Pneumococcal Polysaccharide And Non-Typeable Haemophilus Influenzae (Nthi) Protein D Conjugate Vaccine, Adsorbed [PCV10-GSK];
    • Pneumococcal Polysaccharide Conjugate Vaccine. (Adsorbed) (10-valent) [PCV10-SII];
    • Pneumococcal Conjugate Vaccine, 13-Valent [PCV13];
    • Pneumococcal Polysaccharide Conjugate Vaccine, 15 Valent (Adsorbed) [PCV15]

For the full details on the HTA Council Final Recommendation such as considerations and evidence, please see above links, or refer to the Omnibus HTA Tracker.

The public is encouraged to refer to the electronic PNDF at https://pnf.doh.gov.ph for the most up-to-date information on listed health technologies.

Department-Circular_No.2025-0341Download